Approval · Notice of Compliance 35902 · 2025
IXCHIQ: Notice of Compliance 35902
Issued August 14, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35902
- Date
- August 14, 2025
- Company
- Valneva Austria GmbhVienna, Wien, Austria
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expansion of indication: IXCHIQ (chikungunya vaccine, live, attenuated) Powder for Solution for Intramuscular Injection is a live-attenuated vaccine, intended for active immunization in individuals 12 years and older for the prevention of disease caused by the chikungunya virus (CHIKV), as a single-dose immunization.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IXCHIQ | Not yet assigned | — |
Medicinal ingredients
- CHIKUNGUNYA VIRUS LIVE-ATTENUATED 3 L10T50 per 0.5ML